Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. - Wikidata - wikimedia - TriplyDB

Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.

Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.

http://www.wikidata.org/entity/Q53845804

about

Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease.Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.The logics of leukocytapheresis as a natural biological therapy for inflammatory bowel disease.The role of tumor necrosis factor-alpha in systemic lupus erythematosus Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis.The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review.Inflammatory bowel disease and lupus: a systematic review of the literature.The role of cytokines in the pathogenesis of systemic lupus erythematosus - from bench to bedside.Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders.Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease.Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.Biologics in dermatology: adverse effects.Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis.

P2860

Q26822029-BB7BBFEC-9AEE-4F9F-9981-ED847C56A7DE Q33654733-01198C1C-547D-414E-AD38-7727BE010488 Q35716279-6D98E98E-0BCA-4E7C-9997-D00E44473ADD Q36446929-9E970F33-1416-4D60-80D8-469E1CC72909 Q36641608-3C90E5DC-DA4A-4E5E-80C9-3C9288761F36 Q37220846-B8007C11-60A7-4E96-8E9E-D9EADA01C77F Q37809574-C78C398E-7671-4840-81FD-928EDEB9F339 Q38002687-417CB1ED-7519-4345-84A8-B7AA9B20D5C3 Q38085723-B8EC67B3-E057-4F74-BAED-644CC284D5C5 Q38243723-226F9F19-00E6-4307-9328-15DD2A367070 Q38315640-A62CF135-7020-4AF8-86DB-2A181A07E838 Q40091147-636F48EB-6A4D-42EB-B09B-D68EACFDAF65 Q41120913-B6C61213-A1D5-42D0-88F5-C4E2167D7825 Q42726307-487C1144-911E-4873-9822-F633F448437E

P2860

Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.

http://www.wikidata.org/entity/Q53845804

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Autoantibody profile during sh ...... e: a prospective cohort study.

@en

Autoantibody profile during sh ...... e: a prospective cohort study.

@nl

type

label

Autoantibody profile during sh ...... e: a prospective cohort study.

@en

Autoantibody profile during sh ...... e: a prospective cohort study.

@nl

prefLabel

Autoantibody profile during sh ...... e: a prospective cohort study.

@en

Autoantibody profile during sh ...... e: a prospective cohort study.

@nl

P1433

Q53845804-4065DB3D-458D-4FA9-BBDE-762207E98BF0

P1476

Q53845804-AC59205C-C354-4581-9375-5D6E3094CEDF

P2093

Q53845804-536DFA22-814E-4BE9-96C2-D96A0C37A6F0

Q53845804-62E4612A-B759-49F9-BC05-9756DEFE13DA

Q53845804-85D5A0A1-CB0B-459C-BD5B-529F8E297035

Q53845804-9D526EE2-8439-4922-91CE-B8A5B4BDBFE3

Q53845804-E1959160-1473-46C8-ABF4-58C2086824CB

Q53845804-E8572D79-AED6-44DE-B9E4-76DA492CA9CF

Q53845804-FEB74E48-B666-434E-90AC-5CB6728F22A0

P2860

Q53845804-01A60AD7-4906-4078-B3F7-A36F9F9D882B

Q53845804-05E650DC-A70E-47FC-A180-21E01C51AAE3

Q53845804-246CC20E-34DC-4EB1-A26C-6AFDE1611258

Q53845804-2C813442-593B-47B6-BE8F-A7E5D1A918FE

Q53845804-4340BF80-04A7-4759-9156-5509CF23A892

Q53845804-4E5A9111-DABA-41FD-9474-8D0786E707CB

Q53845804-56A4F3DC-42EB-4D54-BE8A-4CFAD09871D9

Q53845804-6DBF8E6D-A314-4C4C-869A-E2CD333562A9

Q53845804-767AA731-AF43-4F9E-A68F-659D14D52FAF

Q53845804-7D0F4376-8FF9-49FB-9E3B-3B5D264C0866

P304

Q53845804-9D34FBE9-1ED2-4580-A925-5711006C81F3

P31

Q53845804-8236C594-F599-46A0-9DAB-F97DB4D795D7

P356

Q53845804-15DB38FF-3F9B-41BC-9593-95BFA5D908B5

P407

Q53845804-886AB69F-C3A1-42B0-BDB3-3741F3B3D3D6

P433

Q53845804-65D4DDD0-E169-4C95-A13A-F6451DE65928

P478

Q53845804-5ED439B3-DAE7-4C5D-9770-A5E0C964E562

P50

Q53845804-07CD2320-6146-4AD1-B90B-461195D5CA83

P577

Q53845804-C0826ACB-4CC4-4ACA-8DDC-513CB91D5B34

P5875

Q53845804-E06BA8C5-02A8-43D2-86A0-FC931A379472

P698

Q53845804-005C2E2D-5BD3-4E3E-B336-DDDD9EF1E47A

P921

Q53845804-ABE13C31-D67B-4A94-9367-E40358F71275

P356

J.1365-2036.2005.02576.X

P1433

Alimentary Pharmacology & Therapeutics

P1476

Autoantibody profile during sh ...... e: a prospective cohort study.

@en

P2093

Ardizzone S

http://www.w3.org/2001/XMLSchema#string

Atzeni F

http://www.w3.org/2001/XMLSchema#string

Bianchi Porro G

http://www.w3.org/2001/XMLSchema#string

Carrabba M

http://www.w3.org/2001/XMLSchema#string

Colombo E

http://www.w3.org/2001/XMLSchema#string

De Portu S

http://www.w3.org/2001/XMLSchema#string

Maconi G

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study

Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

Infliximab maintenance therapy for fistulizing Crohn's disease

Infliximab for the treatment of fistulas in patients with Crohn's disease.

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.

Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives.

Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms.

Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.

P304

453-461

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2036.2005.02576.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Piercarlo Sarzi-Puttini

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7631592

http://www.w3.org/2001/XMLSchema#string

P698

16128684

http://www.w3.org/2001/XMLSchema#string

P921